Результаты сравнительного клинического исследованиябезопасности, переносимости и эффективностипрепаратов Ронбетал и Бетаферон

1. Гусев Е.И., Бойко А.Н. Современные подходы к использованию бета-интерферонов в лечении рассеянного склероза. Журн. неврол. и психиатр. 2000; 11: 54–9.
2. Гусев Е.И., Завалишин И.А., Бойко А.Н. Рассеянный склероз и другие демиелинизирующие заболевания. М.: Миклош, 2004.
3. Новик А.А., Ионова Т.И. Исследование качества жизни в медицине. Под ред. Ю.Л.Шевченко. М.: ГЭОТАР-Мед, 2004.
4. Шмидт Т.Е., Яхно Н.Н. Рассеянный склероз. М.: Медицина, 2003.
5. Bayas A, Reickmann P. Managing the Adverse Effects of Interferon-b Therapy in Multiple Sclerosis. Drug Safety 2000; 22: 149–59.
6. Chiu AW, Richert N, Ehrmantraut M et al. Heterogeneity in response to interferon beta in patients with multiple sclerosis: a 3-year monthly imaging study. Arch Neurol 2009; 66 (1): 39–43.
7. Durelli L, Ogerro A, Verdun E et al. Does high-dose interferon-beta-1b improve clinical response in more severely disabled multiple sclerosis patients? J Neurol Sci 2000; 178: 37–41.
8. Durelli L, Verdun E et al. The OPTimization of interferon for MS (OPTIMS) trial: a multicenter trial comparating two different doses (250 mg and 375mg) of IFN-b1b. J Neurol Sci 2000; 178: 37–41.
9. Durelli L, Verdun E, Barbero P et al. Every-one-day interferon-beta-1b versus once-weekly interferon-beta-1a for multiple sclerosis: results of a 2-year prospective randomized multicentre study (INCOMIN). Lancet 2002; 359 (9316): 1453–60.
10. ЕМЕА. The rules governing medicinal products in the European Union. Investigation of Bioavailability and Bioequivalence. 1998; 3: 231–44.
11. European Study Group on Interferon-b-1b in Secondary Progressive MA. Placebo-controlled multicentre randomised trial of interferon-b1b in treatment of secondary progressive multiple sclerosis. (by Ludwig Kappos). Lancet 1998; 352: 1491–7.
12. Gaines AR, Varrichio F. Interferon beta-1b injection site reactions and necrosis. Multiple Sclerosis 1998; 4: 70–3.
13. Goodkin DE, CA and the North American Study Group on Interferon-beta-1b in Secondary Progressive MS. Interferon-beta-1b in Secondary Progressive MS: clinical and MRI results of a 3-year randomized controlled trial [abstract no.LBN.004]. 52th Annual Meeting of the American Academy of Neurology Late Breakers; 2000 Apr 29–May 6, San Diego, USA. http//www.fda.gov/cder/biologics/review/ifnbchi031403r2.pdf.
14. IFNB Multiple Sclerosis Study Group, University of British Columbia MS/MRI Analysis Group. Interferon-beta-1b in the treatment of MS; final outcome of the randomized controlled trial. Neurology 1995; 45: 1277–85.
15. IFNB Multiple Sclerosis Study Group. Interferon-beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter randomized, double-blind, placebo-controlled trial. Neurology 1993; 43: 655–61.
16. Knobler RL, Greenstein JI, Johnson KP et al Systemic recombinant human interferon-b treatment of relapsing-remitting multiple sclerosis: pilot study analysis and sox-year follow-up. J Interferon Res 1993; 13 (5): 333–40.
17. Lublin FD, Whitaker JN, Eidelman BH et al. Management of patients receiving interferon beta-1b for multiple sclerosis: report of a consensus conference. Neurology 1996; 46: 12–8.
18. McCormack PL, Scott LJ. Interferon-b1b. A Review of its use in Relapsing-Remitting and Secondary Progressive Multiple Sclerosis. CNS Drugs 2004; 18 (8): 521–6.
19. Miller DH, Molyneux PD, Barker GJ et al. Effect of interferon-beta1b on magnetic resonance imaging outcomes in secondary progressive multiple sclerosis: results of a European multicenter, randomized, double-blind, placebo-controlled trial. European Study Group on Interferon-beta1b in secondary progressive multiple sclerosis. Ann Neurol 1999; 46 (6): 850–9.
20. Mohr DC, Goodkin DE, Likosky W et al. Therapeutic expectations of patients with multiple sclerosis upon initiating interferon beta-1b: relationship to adherence to treatment. Multiple Sclerosis 1996; 2: 222–6.
21. Munschauer FE, Kinkel RP. Managing side effects of Interferon-beta in patients with relapsing-remitting multiple sclerosis. Clin Therap 1997; 19: 883–93.
22. Paty DW, Hartung HP, Ebers GC et al. Management of relapsing-remitting multiple sclerosis: diagnosis and treatment guidelines. Eur J Neurol 1999; 6 (Suppi 1): 1–35.
23. Paty DW, Li DK. Interferon beta-lb is effective in relapsing-remitting multiple sclerosis: II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. The UBC MS/MRI Study Group, the IFNB Multiple Sclerosis Study Group. Neurology 1993; 43: 662–7.
24. Polman HC, Thompson AJ, Murray TJ, McDonald W.I. Multiple Sclerosis: The Guide to Treatment and Management; 5th ed: 25.
25. Rudick RA, Sibley W, Durelli L. Treatment of multiple sclerosis with type I interferons. In «Multiple sclerosis, Advances in Clinical Trial Design, Treatment and Future Perspectives». Springer-Verlag, London, 1996: 230–1.
26. Walther EU, Dang T, Hohlfeld R. Managment of side effects of beta-interferon therapy in MS. Int. MS J 1999; 5: 65–70.
27. Walther EU, Hohlfeld R Multiple sclerosis. Side effects of interferon beta therapy and their management. Neurology 1999; 53: 1622–33.
28. Weber F, Polak T, Gunther A et al. Synergistic immunomodulatory effects of interferon-b1b and the phosphodiesterase inhibitor pentoxyfylline in patients with relapsing-remitting multiple sclerosis. Ann Neurol 1998; 44: 27–34.
29. WHO MS Group. Multiple sclerosis and public health. Educational and management implications. World Health Organization, Department of Mental Health, Neuroscience and Neurological Disorders 1999; 2: 1–11.
30. Zhao Y, Traboulsee A, Petkau AJ, Li D. Regression of new gadolinium enhancing lesion activity in relapsing-remitting multiple sclerosis. Neurology 2008; 70 (13 Pt 2): 1092–7.
31. Zivadinov R, Bakshi R, Central Nervous System Atrophy and Clinical Status in Multiple Sclerosis. J Neuroimaging 2004; 14 (3): 27–35.